Anti-obinutuzumab antibodies in primary membranous nephropathy
Nephrology Dialysis Transplantation · 19.05.2026
DOI: 10.1093/ndt/gfag104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 19.05.2026. Verfasst von Yang Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The First Affiliated Hospital of Shenzhen University (Second People's Hospital of Shenzhen), Shenzhen, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Shenzhen Key Medical Discipline Construction Fund, Sanming Project of Medicine in Shenzhen, Shenzhen High-level Hospital Construction Fund.
Abstract (Originalsprache)
Background
Rituximab is effective first-line therapy for primary membranous nephropathy (PMN), but some patients respond poorly or develop anti-rituximab antibodies (ARA), leading to treatment failure. Obinutuzumab (OBZ), a humanized anti-CD20 monoclonal antibody, shows therapeutic potential in these patients. However, the emergence and clinical relevance of anti-obinutuzumab antibodies (AOA) remain unclear. We aimed to evaluate the role of AOA in PMN patients.
Method
We retrospectively analyzed 23 PMN patients treated with OBZ, including seven AOA-positive cases. Baseline characteristics, immunological, and clinical remission outcomes were compared between AOA-positive and AOA-negative groups. Associations between AOA status, titer, cumulative exposure, and time to remission were assessed.
Results
AOA developed in seven patients (30.4%), exclusively after ≥3 months of therapy [median seroconversion: 12.4 months (8.7–13.6)]. AOA-positive patients were more frequently male (100% vs. 56.3%, P = .036), had higher baseline serum albumin (30.4 ± 6.2 vs. 24.4 ± 6.0 g/l, P = .04), and were more likely ARA-positive (85.7% vs. 18.8%, P = .005). No differences were observed in estimated glomerular filtration rate, urinary protein-to-creatinine ratio, anti-PLA2R titers, or CD19⁺ B-cell counts at baseline. Immunological remission rates were comparable (100% vs. 92.3%, P = .452); clinical remission was achieved in 85.7% vs. 60.0% (P = .228). Kaplan–Meier analysis showed no significant difference in time to clinical (P = .48) or immunological remission (P = .21). Among AOA-positive patients, higher baseline AOA titer (Spearman r = 0.829, P = .042) and greater cumulative AOA exposure (AUC; r = 0.943, P = .017) strongly correlated with delayed clinical remission.
Conclusion
Approximately 30.4% of PMN patients with OBZ therapy were tested positive for AOA. Although no statistically significant association was observed between AOA status and treatment outcomes, higher AOA titers and greater cumulative exposure were associated with slower clinical remission, suggesting a modulatory effect on OBZ efficacy in our PMN cohort.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, The First Affiliated Hospital of Shenzhen University (Second People's Hospital of Shenzhen), Shenzhen, China.
ORCID-Profile: Yuan Cheng
Förderung
- Shenzhen Key Medical Discipline Construction Fund
- Sanming Project of Medicine in Shenzhen
- Shenzhen High-level Hospital Construction Fund
Zitieren
APA
Liu, Y., Cheng, Y., Wu, D., Hu, H., Chen, Y., & Wan, Q. (2026). Anti-obinutuzumab antibodies in primary membranous nephropathy. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag104
Vancouver
Liu Y, Cheng Y, Wu D, Hu H, Chen Y, Wan Q. Anti-obinutuzumab antibodies in primary membranous nephropathy. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag104
BibTeX
@article{Liu2026,
author = {Liu, Yang and Cheng, Yuan and Wu, Di and Hu, Haofei and Chen, Yuna and Wan, Qijun},
title = {Anti-obinutuzumab antibodies in primary membranous nephropathy},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
doi = {10.1093/ndt/gfag104}
}
EUVIMED